|
1
|
Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, Garcia-Gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev 2022; 56:100968. [DOI: 10.1016/j.blre.2022.100968] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Revised: 04/26/2022] [Accepted: 04/27/2022] [Indexed: 12/14/2022]
|
|
2
|
Efficace F, Baccarani M. Quality of Life Improvements in Patients with Chronic Myeloid Leukemia after Stopping Long-Term Therapy: Who Can Benefit the Most? J Natl Cancer Inst 2021; 114:9-11. [PMID: 34491364 DOI: 10.1093/jnci/djab185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 09/02/2021] [Indexed: 11/14/2022] Open
Affiliation(s)
- Fabio Efficace
- Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit. Rome, Italy
| | - Michele Baccarani
- Department of Hematology, "L. and A Seràgnoli" University of Bologna and St.Orsola-Malpighi University Hospital, Bologna, Italy
| |
Collapse
|